COG1

Summary

COG1 (component of oligomeric golgi complex 1, HGNC:6545) is a protein-coding gene on chromosome 17q25.1, encoding Conserved oligomeric Golgi complex subunit 1 (Q8WTW3). Required for normal Golgi function. It is a selective cancer dependency (DepMap: 52.8% of cell lines).

The protein encoded by this gene is one of eight proteins (Cog1-8) which form a Golgi-localized complex (COG) required for normal Golgi morphology and function. It is thought that this protein is required for steps in the normal medial and trans Golgi-associated processing of glycoconjugates and plays a role in the organization of the Golgi-localized complex.

Source: NCBI Gene 9382 — RefSeq curated summary.

At a glance

• Gene–disease (curated): COG1-congenital disorder of glycosylation (Definitive, GenCC)
• Clinical variants (ClinVar): 508 total — 12 pathogenic, 5 likely-pathogenic
• Phenotypes (HPO): 91
• Druggable target: yes
• Cancer dependency (DepMap): dependent in 52.8% of screened cell lines
• Dosage sensitivity (ClinGen): haploinsufficiency autosomal recessive, triplosensitivity unscored
• MANE Select transcript: NM_018714

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:6545
Approved symbol	COG1
Name	component of oligomeric golgi complex 1
Location	17q25.1
Locus type	gene with protein product
Status	Approved
Aliases	KIAA1381
Ensembl gene	ENSG00000166685
Ensembl biotype	protein_coding
OMIM	606973
Entrez	9382

Gene structure

Transcript identifiers

Ensembl transcripts: 15 — 10 protein_coding, 3 retained_intron, 2 nonsense_mediated_decay

ENST00000299886, ENST00000438720, ENST00000577238, ENST00000577844, ENST00000580271, ENST00000582512, ENST00000582587, ENST00000582672, ENST00000582973, ENST00000876963, ENST00000876964, ENST00000876965, ENST00000923183, ENST00000947884, ENST00000947885

RefSeq mRNA: 1 — MANE Select: NM_018714 NM_018714

CCDS: CCDS11692

Canonical transcript exons

ENST00000299886 — 14 exons

Exon	Start	End
ENSE00001105601	73206708	73206817
ENSE00001105604	73197226	73197396
ENSE00001105614	73196507	73196751
ENSE00001105619	73203632	73203793
ENSE00001105631	73201109	73201900
ENSE00001105640	73205553	73205680
ENSE00001105647	73203000	73203146
ENSE00001105651	73196900	73197081
ENSE00001136834	73200566	73200776
ENSE00001136838	73199865	73200021
ENSE00002719633	73193055	73193384
ENSE00003501326	73207181	73207256
ENSE00003525871	73206154	73206262
ENSE00003601993	73208314	73208507

Expression profiles

Bgee: expression breadth ubiquitous, 252 present calls, max score 95.76.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 22.9904 / max 128.3385, expressed in 1810 samples.

FANTOM5 promoters (1 alternative TSS)

Promoter ID	TPM avg	Samples expressed
162563	22.9904	1810

Top tissues by expression

260 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
right hemisphere of cerebellum	UBERON:0014890	95.76	gold quality
cerebellar hemisphere	UBERON:0002245	95.68	gold quality
apex of heart	UBERON:0002098	95.64	gold quality
cerebellar cortex	UBERON:0002129	95.59	gold quality
right frontal lobe	UBERON:0002810	95.05	gold quality
cerebellum	UBERON:0002037	95.00	gold quality
adenohypophysis	UBERON:0002196	94.91	gold quality
Brodmann (1909) area 9	UBERON:0013540	94.83	gold quality
nucleus accumbens	UBERON:0001882	94.69	gold quality
pituitary gland	UBERON:0000007	94.54	gold quality
prefrontal cortex	UBERON:0000451	94.34	gold quality
anterior cingulate cortex	UBERON:0009835	94.25	gold quality
hindlimb stylopod muscle	UBERON:0004252	94.00	gold quality
caudate nucleus	UBERON:0001873	93.83	gold quality
body of pancreas	UBERON:0001150	93.72	gold quality
heart left ventricle	UBERON:0002084	93.70	gold quality
dorsolateral prefrontal cortex	UBERON:0009834	93.61	gold quality
gastrocnemius	UBERON:0001388	93.55	gold quality
right uterine tube	UBERON:0001302	93.54	gold quality
amygdala	UBERON:0001876	93.48	gold quality
putamen	UBERON:0001874	93.35	gold quality
cardiac ventricle	UBERON:0002082	93.30	gold quality
frontal cortex	UBERON:0001870	93.27	gold quality
frontal lobe	UBERON:0016525	93.27	gold quality
muscle of leg	UBERON:0001383	93.08	gold quality
endocervix	UBERON:0000458	92.99	gold quality
neocortex	UBERON:0001950	92.95	gold quality
right ovary	UBERON:0002118	92.90	gold quality
left ovary	UBERON:0002119	92.69	gold quality
muscle layer of sigmoid colon	UBERON:0035805	92.48	gold quality

Single-cell (SCXA)

Detected in 2 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	4.71
E-MTAB-10137	no	516.06

Regulation

Is transcription factor: no

Functional genomics

ClinGen dosage: haploinsufficiency 30 (autosomal recessive), triplosensitivity Not yet evaluated (unscored). ClinGen Gene Dosage Map DepMap (CRISPR cell-line fitness): dependent in 52.8% of screened cell lines.

Literature-anchored findings (GeneRIF, showing 5)

• Sec34 is implicated in traffic from the endoplasmic reticulum to the Golgi and exists in a complex with GTC-90 and ldlBp (PMID:11929878)
• These findings support the proposal that COG is directly involved in controlling vesicular retrograde transport of Golgi resident proteins throughout the Golgi apparatus. (PMID:16857184)
• A novel mutation in COG1 was found in two patients with a cerebrocostomandibular-like syndrome. (PMID:19008299)
• This study reports a novel set of Dengue virus (DENV) NS1-interacting host cell proteins in the HepG2 cell line and proposes possible roles for human NEK2, TAO1, and COG1 in DENV infection. (PMID:27108190)
• Chronic renal patients with more atherogenic lipoprotein LDL B phenotype are in advanced state of oxidative stress compared with control subjects. (PMID:27412679)

Cross-species orthologs

5 orthologs

Organism	Symbol	Gene ID
danio_rerio	cog1	ENSDARG00000105131
mus_musculus	Cog1	ENSMUSG00000018661
rattus_norvegicus	Cog1	ENSRNOG00000002795
drosophila_melanogaster	Cog1	FBGN0037998
caenorhabditis_elegans	cogc-1	WBGENE00003258

Protein

Protein identifiers

Conserved oligomeric Golgi complex subunit 1 — Q8WTW3 (reviewed: Q8WTW3)

Alternative names: Component of oligomeric Golgi complex 1

All UniProt accessions (6): E9PBL8, J3KRP4, J3KSY3, J3QKY9, J3QLT5, Q8WTW3

UniProt curated annotations — full annotation on UniProt →

Function. Required for normal Golgi function.

Subunit / interactions. Component of the conserved oligomeric Golgi complex which is composed of eight different subunits and is required for normal Golgi morphology and localization.

Subcellular location. Golgi apparatus membrane.

Disease relevance. Congenital disorder of glycosylation 2G (CDG2G) [MIM:611209] A multisystem disorder caused by a defect in glycoprotein biosynthesis and characterized by under-glycosylated serum glycoproteins. Congenital disorders of glycosylation result in a wide variety of clinical features, such as defects in the nervous system development, psychomotor retardation, dysmorphic features, hypotonia, coagulation disorders, and immunodeficiency. The broad spectrum of features reflects the critical role of N-glycoproteins during embryonic development, differentiation, and maintenance of cell functions. Clinical features of CDG2G include failure to thrive, generalized hypotonia, growth retardation and mild psychomotor retardation. CDG2G is biochemically characterized by a defect in O-glycosylation as well as N-glycosylation. The disease is caused by variants affecting the gene represented in this entry.

Similarity. Belongs to the COG1 family.

RefSeq proteins (1): NP_061184* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR033370	COG1	Family

Pfam: PF08700

UniProt features (7 total): sequence variant 3, modified residue 2, initiator methionine 1, chain 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q8WTW3-F1	77.82	0.40

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (2): 2, 7

Function

Pathways and Gene Ontology

Reactome pathways

4 pathways

ID	Pathway
R-HSA-6807878	COPI-mediated anterograde transport
R-HSA-6811438	Intra-Golgi traffic
R-HSA-6811440	Retrograde transport at the Trans-Golgi-Network
R-HSA-9918481	Dengue Virus-Host Interactions

MSigDB gene sets: 289 (showing top): GRAESSMANN_APOPTOSIS_BY_SERUM_DEPRIVATION_DN, GRAESSMANN_APOPTOSIS_BY_DOXORUBICIN_DN, GOBP_VESICLE_MEDIATED_TRANSPORT, REACTOME_MEMBRANE_TRAFFICKING, GOBP_INTRA_GOLGI_VESICLE_MEDIATED_TRANSPORT, GOCC_TRANS_GOLGI_NETWORK, GOBP_ENDOMEMBRANE_SYSTEM_ORGANIZATION, NIKOLSKY_BREAST_CANCER_17Q21_Q25_AMPLICON, GOBP_GOLGI_ORGANIZATION, GOCC_GOLGI_TRANSPORT_COMPLEX, GOCC_TRANS_GOLGI_NETWORK_MEMBRANE, GOCC_ORGANELLE_SUBCOMPARTMENT, GOBP_GOLGI_VESICLE_TRANSPORT, HATADA_METHYLATED_IN_LUNG_CANCER_UP, REACTOME_POST_TRANSLATIONAL_PROTEIN_MODIFICATION

GO Biological Process (5): retrograde transport, vesicle recycling within Golgi (GO:0000301), intra-Golgi vesicle-mediated transport (GO:0006891), Golgi organization (GO:0007030), protein transport (GO:0015031), obsolete glycosylation (GO:0070085)

GO Molecular Function (1): protein binding (GO:0005515)

GO Cellular Component (5): Golgi membrane (GO:0000139), Golgi apparatus (GO:0005794), COG complex (GO:0017119), trans-Golgi network membrane (GO:0032588), membrane (GO:0016020)

Reactome top-level categories

Rollup of top-3 pathways:

Category	Pathways
Intra-Golgi and retrograde Golgi-to-ER traffic	2
ER to Golgi Anterograde Transport	1
Dengue Virus Infection	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
Golgi apparatus	2
intra-Golgi vesicle-mediated transport	1
Golgi vesicle transport	1
organelle organization	1
endomembrane system organization	1
transport	1
intracellular protein localization	1
establishment of protein localization	1
binding	1
bounding membrane of organelle	1
cytoplasm	1
endomembrane system	1
intracellular membrane-bounded organelle	1
vesicle tethering complex	1
trans-Golgi network	1
organelle membrane	1
cellular anatomical structure	1

Protein interactions and networks

STRING

1254 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
COG1	COG5	Q9UP83	996
COG1	COG2	Q14746	996
COG1	COG8	Q96MW5	996
COG1	COG7	P83436	995
COG1	COG4	Q9H9E3	994
COG1	COG3	Q96JB2	992
COG1	COG6	Q9Y2V7	976
COG1	RINT1	Q6NUQ1	795
COG1	GOSR2	O14653	726
COG1	STX5	Q13190	716
COG1	COPB1	P53618	667
COG1	STX16	O14662	664
COG1	VPS51	Q9UID3	656
COG1	VPS53	Q5VIR6	652
COG1	GOLPH3	Q9H4A6	632

IntAct

95 interactions, top by confidence:

A	B	Type	Score
ODAD1	HGS	psi-mi:“MI:0914”(association)	0.850
CFTR	ESYT2	psi-mi:“MI:2364”(proximity)	0.710
SCN2B	EXOC5	psi-mi:“MI:0914”(association)	0.640
COMMD8	VPS26C	psi-mi:“MI:0914”(association)	0.640
COG3	COG7	psi-mi:“MI:0914”(association)	0.640
COG7	ILVBL	psi-mi:“MI:0914”(association)	0.640
GYPA	TCAF2	psi-mi:“MI:0914”(association)	0.640
SLC16A3	CASK	psi-mi:“MI:0914”(association)	0.590
COG1	COG4	psi-mi:“MI:0915”(physical association)	0.560
COG6	EXOC5	psi-mi:“MI:0914”(association)	0.530
CD274	TTI1	psi-mi:“MI:0914”(association)	0.530
GYPB	TCAF2	psi-mi:“MI:0914”(association)	0.530
COG5	BSG	psi-mi:“MI:0914”(association)	0.530
COG3	TBCC	psi-mi:“MI:0914”(association)	0.530
CD40	EXOC5	psi-mi:“MI:0914”(association)	0.530
NPTN	TNPO2	psi-mi:“MI:0914”(association)	0.530
COG2	COG7	psi-mi:“MI:0914”(association)	0.530
ILVBL	SLC33A1	psi-mi:“MI:0914”(association)	0.530
COG1	CDC42	psi-mi:“MI:0915”(physical association)	0.370
Bap1	RNF40	psi-mi:“MI:0914”(association)	0.350
Sgo2a	SORBS3	psi-mi:“MI:0914”(association)	0.350
CAPN1	ANKRD17	psi-mi:“MI:0914”(association)	0.350

BioGRID (147): COG1 (Biochemical Activity), COG1 (Affinity Capture-MS), COG1 (Affinity Capture-MS), COG1 (Affinity Capture-MS), COG1 (Affinity Capture-MS), COG1 (Affinity Capture-MS), COG1 (Affinity Capture-MS), COG1 (Co-fractionation), COG1 (Co-fractionation), COG1 (Co-fractionation), COG1 (Co-fractionation), COG1 (Co-fractionation), COG1 (Co-fractionation), COG7 (Co-fractionation), COG1 (Affinity Capture-MS)

ESM2 similar proteins: A2VDR8, A4IF89, B1AY13, B1WC10, F4HQ84, F4I4B6, F4JHH5, O00471, O15068, O54921, O54924, P0CI65, P83436, P97878, Q14746, Q2TBH9, Q3T1G7, Q3TPX4, Q3UM29, Q5U247, Q5ZJ43, Q62717, Q6DK84, Q6GLR7, Q6NMI3, Q6NUQ1, Q6PGF7, Q7TNH6, Q7Z494, Q80TJ1, Q86UW7, Q8BYR5, Q8BZ36, Q8C0L8, Q8C456, Q8CI04, Q8IYI6, Q8L838, Q8WTW3, Q921L5

Diamond homologs: Q8WTW3, Q9Z160

SIGNOR signaling

1 interactions.

A	Effect	B	Mechanism
COG1	“form complex”	“COG tethering complex”	binding

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 108 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

Pathway	Partners	Fold	FDR
Intra-Golgi traffic	7	27.1×	1e-06
Retrograde transport at the Trans-Golgi-Network	7	22.9×	2e-06
COPI-mediated anterograde transport	11	18.0×	7e-09

GO biological processes:

GO term	Partners	Fold	FDR
intra-Golgi vesicle-mediated transport	5	28.9×	9e-05
retrograde vesicle-mediated transport, Golgi to endoplasmic reticulum	6	22.2×	4e-05
Golgi organization	11	16.2×	2e-08
protein transport	13	6.3×	3e-05
cell surface receptor signaling pathway	8	5.6×	7e-03

Disease & clinical

Clinical variants and AI predictions

ClinVar

508 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	12
Likely pathogenic	5
Uncertain significance	250
Likely benign	156
Benign	37

Top pathogenic / likely-pathogenic (17)

Variant ID	HGVS	Classification
1480682	NM_018714.3(COG1):c.1130del (p.Lys377fs)	Pathogenic
2027635	NM_018714.3(COG1):c.2686C>T (p.Gln896Ter)	Pathogenic
2028309	NM_018714.3(COG1):c.254dup (p.Tyr86fs)	Pathogenic
2805911	NM_018714.3(COG1):c.1091del (p.Asn364fs)	Pathogenic
3243069	NC_000017.10:g.(?71195984)(71199305_?)del	Pathogenic
3684462	NM_018714.3(COG1):c.1401dup (p.Glu468Ter)	Pathogenic
3728028	NM_018714.3(COG1):c.2665del (p.Arg889fs)	Pathogenic
3728286	NM_018714.3(COG1):c.2665_2666insCG (p.Arg889fs)	Pathogenic
4710995	NM_018714.3(COG1):c.415C>T (p.Gln139Ter)	Pathogenic
4740975	NM_018714.3(COG1):c.2626_2629dup (p.Gly877fs)	Pathogenic
4764410	NM_018714.3(COG1):c.1717C>T (p.Gln573Ter)	Pathogenic
4780564	NM_018714.3(COG1):c.1487del (p.Gly496fs)	Pathogenic
2098246	NM_018714.3(COG1):c.561-1G>A	Likely pathogenic
450371	NM_018714.3(COG1):c.2084_2085insCCTGGTAATAAAATGAC (p.His695_Gly696insLeuValIleLysTer)	Likely pathogenic
452106	NM_018714.3(COG1):c.1823del (p.Leu608fs)	Likely pathogenic
4845691	NM_018714.3(COG1):c.338del (p.Lys113fs)	Likely pathogenic
4849349	NM_018714.3(COG1):c.415_416del (p.Gln139fs)	Likely pathogenic

SpliceAI

2125 predictions. Top by Δscore:

Variant	Effect	Δscore
17:73193381:GCAG:G	donor_gain	1.0000
17:73193382:CAG:C	donor_loss	1.0000
17:73193383:AGG:A	donor_loss	1.0000
17:73193385:GTCA:G	donor_loss	1.0000
17:73193386:T:A	donor_loss	1.0000
17:73196479:T:TA	acceptor_gain	1.0000
17:73196486:GTTCT:G	acceptor_gain	1.0000
17:73200562:GCAGG:G	acceptor_loss	1.0000
17:73200563:CAGGT:C	acceptor_loss	1.0000
17:73200564:AGGTG:A	acceptor_loss	1.0000
17:73200565:GGT:G	acceptor_gain	1.0000
17:73200774:CAGGT:C	donor_loss	1.0000
17:73200775:AGGTG:A	donor_loss	1.0000
17:73200777:GT:G	donor_loss	1.0000
17:73200778:T:G	donor_loss	1.0000
17:73201897:GAAA:G	donor_gain	1.0000
17:73201901:G:GG	donor_gain	1.0000
17:73203630:A:AG	acceptor_gain	1.0000
17:73203631:G:GA	acceptor_gain	1.0000
17:73203631:GC:G	acceptor_gain	1.0000
17:73203631:GCC:G	acceptor_gain	1.0000
17:73203794:G:GA	donor_loss	1.0000
17:73203795:T:A	donor_loss	1.0000
17:73205697:G:GT	donor_gain	1.0000
17:73206152:A:AG	acceptor_gain	1.0000
17:73206152:A:AT	acceptor_loss	1.0000
17:73206153:G:GA	acceptor_gain	1.0000
17:73206153:GA:G	acceptor_gain	1.0000
17:73206153:GAA:G	acceptor_gain	1.0000
17:73206153:GAAT:G	acceptor_gain	1.0000

AlphaMissense

6395 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
17:73193245:T:C	L59P	0.997
17:73201253:T:A	W476R	0.997
17:73201253:T:C	W476R	0.997
17:73206197:T:C	F852L	0.997
17:73206199:T:A	F852L	0.997
17:73206199:T:G	F852L	0.997
17:73206204:T:C	L854P	0.997
17:73193212:T:C	L48P	0.996
17:73193253:G:C	A62P	0.996
17:73200011:T:A	W354R	0.996
17:73200011:T:C	W354R	0.996
17:73203072:T:A	W716R	0.996
17:73203072:T:C	W716R	0.996
17:73207182:T:C	F911L	0.996
17:73207184:T:A	F911L	0.996
17:73207184:T:G	F911L	0.996
17:73193158:T:C	I30T	0.995
17:73193256:G:C	A63P	0.995
17:73206210:T:A	V856D	0.994
17:73193158:T:G	I30S	0.993
17:73193275:T:C	M69T	0.993
17:73201880:T:A	W685R	0.993
17:73201880:T:C	W685R	0.993
17:73206192:A:G	D850G	0.993
17:73193239:G:C	R57P	0.992
17:73201358:A:C	S511R	0.992
17:73201360:C:A	S511R	0.992
17:73201360:C:G	S511R	0.992
17:73203139:C:A	P738H	0.992
17:73207192:T:A	L914H	0.992

dbSNP variants (sampled 300 via entrez): RS1000000100 (17:73197532 C>T), RS1000096890 (17:73204165 T>C), RS1000215245 (17:73207469 C>G,T), RS1000295130 (17:73194570 T>C), RS1000456428 (17:73197855 C>T), RS1000820588 (17:73193364 C>G,T), RS1001117345 (17:73202969 G>A,C), RS1001340831 (17:73203413 G>A), RS1001409233 (17:73199009 C>T), RS1001529501 (17:73206618 G>A), RS1001790525 (17:73203719 C>T), RS1001923742 (17:73208145 G>A,T), RS1002062067 (17:73206888 G>A), RS1002115360 (17:73202173 T>TA), RS1002271206 (17:73207865 A>G)

Disease associations

OMIM: gene MIM:606973 | disease phenotypes: MIM:611209

GenCC curated gene-disease

Disease	Classification	Inheritance
COG1-congenital disorder of glycosylation	Definitive	Autosomal recessive

ClinGen Gene-Disease Validity (1)

Expert-panel classifications — Definitive > Strong > Moderate > Limited > Disputed > Refuted.

Disease	Classification	Inheritance
COG1-congenital disorder of glycosylation	Moderate	AR

Mondo (3): COG1-congenital disorder of glycosylation (MONDO:0012637), prostate cancer (MONDO:0008315), intellectual disability (MONDO:0001071)

Orphanet (3): COG1-CDG (Orphanet:263508), Familial prostate cancer (Orphanet:1331), NON RARE IN EUROPE: Unexplained intellectual disability (Orphanet:319658)

HPO phenotypes

91 total (30 of 91 shown, HPO-id order):

HPO	Term
HP:0000007	Autosomal recessive inheritance
HP:0000028	Cryptorchidism
HP:0000047	Hypospadias
HP:0000083	Renal insufficiency
HP:0000126	Hydronephrosis
HP:0000160	Narrow mouth
HP:0000162	Glossoptosis
HP:0000175	Cleft palate
HP:0000201	Pierre-Robin sequence
HP:0000218	High palate
HP:0000219	Thin upper lip vermilion
HP:0000252	Microcephaly
HP:0000253	Progressive microcephaly
HP:0000274	Small face
HP:0000316	Hypertelorism
HP:0000319	Smooth philtrum
HP:0000343	Long philtrum
HP:0000347	Micrognathia
HP:0000358	Posteriorly rotated ears
HP:0000369	Low-set ears
HP:0000402	Stenosis of the external auditory canal
HP:0000405	Conductive hearing impairment
HP:0000431	Wide nasal bridge
HP:0000463	Anteverted nares
HP:0000470	Short neck
HP:0000475	Broad neck
HP:0000494	Downslanted palpebral fissures
HP:0000520	Proptosis
HP:0000582	Upslanted palpebral fissure
HP:0000750	Delayed speech and language development

GWAS associations

0 associations (top):

MeSH disease descriptors (3)

Descriptor	Name	Tree numbers
D008607	Intellectual Disability	C10.597.606.360; C23.888.592.604.646; F01.700.687; F03.625.539
D011471	Prostatic Neoplasms	C04.588.945.440.770; C12.100.500.260.750; C12.100.500.565.625; C12.200.294.260.750; C12.200.294.565.625; C12.200.758.409.750; C12.900.619.750
C535756	Congenital disorder of glycosylation, type 2G (supp.)

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL4105805 (SINGLE PROTEIN)

PharmGKB: 1 entry (VIP=true, CPIC=false)

ChEMBL bioactivities

2 potent at pChembl≥5 of 4 total, top 2 by pChembl (potency: 10 = 0.1 nM, 6 = 1 µM).

pChembl	Type	Value	Unit	Molecule
8.41	Kd	3.9	nM	CHEMBL3752910
8.41	ED50	3.9	nM	CHEMBL3752910

PubChem BioAssay actives

1 with measured affinity, of 6 total; 1 most potent distinct compounds. Largely complementary to BindingDB; screening values are coarse (µM, 4 dp), so sub-nM hits tie at the floor.

Compound	Assay	Type	Value	Unit
4-methyl-3-[(1-methyl-6-pyridin-3-ylpyrazolo[3,4-d]pyrimidin-4-yl)amino]-N-[3-(trifluoromethyl)phenyl]benzamide	2148104: Binding affinity to human COG1 incubated for 45 mins by Kinobead based pull down assay	kd	0.0039	uM

CTD chemical–gene interactions

28 total (human), top 28 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	affects expression, decreases expression, increases methylation	3
aristolochic acid I	increases expression	1
FR900359	decreases phosphorylation	1
2,4,6-tribromophenol	decreases expression	1
bisphenol A	decreases expression	1
decabromobiphenyl ether	decreases expression	1
sodium arsenite	increases expression	1
tetrabromobisphenol A	increases expression	1
coumarin	decreases phosphorylation	1
di-n-butylphosphoric acid	affects expression	1
abrine	increases expression	1
pentabrominated diphenyl ether 100	decreases expression	1
hexabrominated diphenyl ether 153	decreases expression	1
bisphenol S	increases methylation	1
Temozolomide	increases expression	1
Sunitinib	increases expression	1
Arsenic	affects methylation	1
Benzo(a)pyrene	increases methylation	1
Doxorubicin	decreases expression	1
Ethyl Methanesulfonate	increases expression	1
Ivermectin	decreases expression	1
Smoke	decreases expression	1
Urethane	decreases expression	1
Cyclosporine	increases expression	1
Aflatoxin B1	increases expression	1
Asbestos, Crocidolite	decreases expression	1
Thapsigargin	increases expression	1
Copper Sulfate	decreases expression	1

ChEMBL screening assays

2 unique, capped per target: 2 binding

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL4012601	Binding	Binding affinity to COG1 in human INA-6 cells after 3 hrs by nanoLC-MS/MS method	Ugi Reaction-Derived α-Acyl Aminocarboxamides Bind to Phosphatidylinositol 3-Kinase-Related Kinases, Inhibit HSF1-Dependent Heat Shock Response, and Induce Apoptosis in Multiple Myeloma Cells. — J Med Chem

Cellosaurus cell lines

1 cell lines: 1 cancer cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_A637	KMS-18	Cancer cell line	Male

Clinical trials (associated diseases)

300 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00029224	PHASE4	COMPLETED	Treatment With Zoledronic Acid in Patients With Breast Cancer, Multiple Myeloma, and Prostate Cancer With Cancer Related Bone Lesions
NCT00035997	PHASE4	COMPLETED	Open-label Trial on the Effect of I.V. Zoledronic Acid 4 mg on Bone Density in Hormone Sensitive Prostate Cancer Patients With Bone Metastasis
NCT00063609	PHASE4	COMPLETED	The Effect of Zoledronic Acid on Bone Loss in Prostate Cancer Patients Undergoing Androgen Deprivation Therapy
NCT00103623	PHASE4	SUSPENDED	The Plenaxis® Experience Study
NCT00106392	PHASE4	COMPLETED	A Safety and Efficacy Study of Prograf in the Prevention of Erectile Dysfunction After Radical Prostatectomy
NCT00185029	PHASE4	UNKNOWN	MR-Lymphography and Lymph Node Staging in Prostate Cancer
NCT00199485	PHASE4	COMPLETED	Angelica Sinensis for the Treatment of Hot Flashes in Men Undergoing LHRH Therapy for Prostate Cancer
NCT00219219	PHASE4	COMPLETED	Zoledronic Acid in the Prevention of Skeletal-related Events in Hormone Refractory and Hormone-sensitive Prostate Cancer Patients With Bone Metastases
NCT00219271	PHASE4	COMPLETED	Effect Of Zoledronic Acid On Circulating And Bone Marrow-Residing Prostate Cancer Cells In Patients With Clinically Localized Prostate Cancer
NCT00237146	PHASE4	COMPLETED	Study to Evaluate Zoledronic Acid on Quality of Life and Skeletal-related Events as Adjuvant Treatment in Patients With Hormone-naïve Prostate Cancer and Bone Metastasis Who Have Undergone Orchiectomy
NCT00242554	PHASE4	COMPLETED	Open-label Phase IV Clinical Trial to Evaluate the Safety and Tolerability of Zoledronic Acid in Patients With Prostate Cancer and Bone Metastases
NCT00280098	PHASE4	COMPLETED	Docetaxel in the Treatment of Hormone Refractory Prostate Cancer
NCT00293696	PHASE4	COMPLETED	Casodex/Zoladex Biomarkers in Localised Prostate Cancer
NCT00334139	PHASE4	COMPLETED	Effect of Zoledronic Acid on Bone Metabolism in Patients With Bone Metastasis and Prostate or Breast Cancer
NCT00375765	PHASE4	COMPLETED	Effects On Dihydrotestosterone Regulated Gene Expression In Benign Prostatic Hyperplasia Or Prostate Cancer
NCT00391690	PHASE4	COMPLETED	Evaluation of Bone Markers as Diagnostic Tools for Early Detection of Bone Metastases in Patients With High Risk Prostate Cancer
NCT00422708	PHASE4	COMPLETED	Local Anesthesia for Prostate Biopsy
NCT00526331	PHASE4	COMPLETED	Evaluation of Arterial Pressure Based Cardiac Output for Goal-Directed Perioperative Therapy
NCT00590213	PHASE4	COMPLETED	Compare the Value of Prophylactic Versus Therapeutic Breast Radiotherapy in CASODEX
NCT00629330	PHASE4	TERMINATED	Dissemination of Prostate Cancer Screening to PCP’s in African American Communities
NCT00771966	PHASE4	COMPLETED	Radical Prostatectomy and Perioperative Fluid Therapy
NCT00805701	PHASE4	COMPLETED	Study Assessing The Efficacy And Safety Of Avodart (Dutasteride) At Improving Urinary Symptoms In Men With Prostate Cancer Who Are Undergoing Seed Implantation
NCT00859027	PHASE4	COMPLETED	Effect Of Risedronate On Bone Mass In Older Men Receiving Neoadjuvant Therapy For Prostate Cancer
NCT00906269	PHASE4	UNKNOWN	Can Hyperbaric Oxygen Improve Erectile Function Following Surgery for Prostate Cancer
NCT00953277	PHASE4	COMPLETED	Study of Nerve Reconstruction Using AVANCE in Subjects Who Undergo Robotic Assisted Prostatectomy for Treatment of Prostate Cancer
NCT00982800	PHASE4	COMPLETED	Does Postoperative Gabapentin Reduce Pain, Opioid Consumption and Anxiety and Have a Positive Effect on Health Related Quality of Life After Radical Prostatectomy?
NCT01083199	PHASE4	COMPLETED	Global Performance Evaluation of the AMS CONTINUUM™ Device
NCT01136226	PHASE4	COMPLETED	Evaluate Recovery of Testosterone for Patients Using Eligard
NCT01161563	PHASE4	COMPLETED	Randomized Crossover Trial to Assess the Tolerability of Gonadotropin Releasing Hormone (GnRH) Analogue Administration
NCT01230905	PHASE4	COMPLETED	Study to Monitor the Effects of Androgen Suppression Treatment on the Heart
NCT01296672	PHASE4	COMPLETED	3 Month Finasteride Challenge Test Can Significantly Improve the Performance of Screening for Prostate Cancer
NCT01365143	PHASE4	TERMINATED	Prospective Randomized Trial Comparing Robotic Versus Open Radical Prostatectomy
NCT01379742	PHASE4	UNKNOWN	Comparison of Between ThinSeed™ and OncoSeed™ for Permanent Prostate Brachytherapy
NCT01486563	PHASE4	COMPLETED	Hydroxyethyl Starch and Renal Function After Radical Prostatectomy
NCT01511874	PHASE4	COMPLETED	Efficacy and Safety Study of ELIGARD 22.5mg With Prostate Cancer
NCT01512472	PHASE4	TERMINATED	Firmagon (Degarelix) Intermittent Therapy
NCT01547416	PHASE4	COMPLETED	The Effect of Combined General/Epidural Anesthesia Versus General Anesthesia on Diaphragmatic Function
NCT01571544	PHASE4	COMPLETED	The Use of Thermal Suits as Preventing Hypothermia During Surgery
NCT01581749	PHASE4	UNKNOWN	Evaluation of Truebeam for Low-Intermediate Risk Prostate Cancer
NCT01649635	PHASE4	COMPLETED	Study of Cabazitaxel Combined With Prednisone and Prophylaxis of Neutropenia Complications in the Treatment of Patients With Metastatic Castration-resistant Prostate Cancer